Ozurdex for patients with macular edema secondary to intraocular vasular tumors
Not Applicable
- Conditions
- Health Condition 1: H318- Other specified disorders of choroid
- Registration Number
- CTRI/2021/11/038270
- Lead Sponsor
- V Prasad Eye Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Newly diagnosed patients with CME secondary to intraocular vascular tumors
2.Participant is willing and able to give informed consent for participation in the study.
3.Male and Female, aged 10 years or above.
4.BCVA 20/32 to 20/400 inclusive
5.Central subfoveal OCT thickness > 300 microns
Exclusion Criteria
1.Any co-existing ocular disease other than intraocular tumor which might cause macular edema.
2.Intraocular surgery within 3 months
3.History of IOP elevation in response to steroid treatment in either eye.
4.History of glaucoma or optic nerve head change consistent with glaucoma damage, and/or glaucomatous visual field loss in the study eye.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.BCVA as per ETDRS chart (distance & near acuity) <br/ ><br>2.Central subfoveal thickness on OCT <br/ ><br>3.Wide-field fundus photograph <br/ ><br>4.B scan to document the tumor dimensions <br/ ><br>5.IOP <br/ ><br>Timepoint: 3 months & 6 months
- Secondary Outcome Measures
Name Time Method 1.BCVA as per ETDRS chart (distance & near acuity) <br/ ><br>2.Central subfoveal thickness on OCT <br/ ><br>3.Wide-field fundus photograph <br/ ><br>4.B scan to document the tumor dimensions <br/ ><br>5.IOP <br/ ><br>Timepoint: 3 months,6 months